Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 1
2004 1
2005 6
2006 8
2007 6
2008 7
2009 6
2010 7
2011 2
2012 2
2013 11
2014 8
2015 7
2016 10
2017 12
2018 9
2019 13
2020 18
2021 36
2022 18
2023 11
2024 15
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

195 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic drug monitoring of oral targeted antineoplastic drugs.
Mueller-Schoell A, Groenland SL, Scherf-Clavel O, van Dyk M, Huisinga W, Michelet R, Jaehde U, Steeghs N, Huitema ADR, Kloft C. Mueller-Schoell A, et al. Among authors: kloft c. Eur J Clin Pharmacol. 2021 Apr;77(4):441-464. doi: 10.1007/s00228-020-03014-8. Epub 2020 Nov 9. Eur J Clin Pharmacol. 2021. PMID: 33165648 Free PMC article. Review.
Forecasting antimicrobial resistance evolution.
Rolff J, Bonhoeffer S, Kloft C, Leistner R, Regoes R, Hochberg ME. Rolff J, et al. Among authors: kloft c. Trends Microbiol. 2024 Aug;32(8):736-745. doi: 10.1016/j.tim.2023.12.009. Epub 2024 Jan 18. Trends Microbiol. 2024. PMID: 38238231 Review.
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort.
Mc Laughlin AM, Helland T, Klima F, Koolen SLW, van Schaik RHN, Mathijssen RHJ, Neven P, Swen JJ, Guchelaar HJ, Dalenc F, White-Koning M, Michelet R, Mikus G, Schroth W, Mürdter T, Brauch H, Schwab M, Søiland H, Mellgren G, Thomas F, Kloft C, Hertz DL; CYP2D6 Endoxifen Percentage Activity Model (CEPAM) Consortium. Mc Laughlin AM, et al. Among authors: kloft c. Clin Pharmacol Ther. 2024 Sep;116(3):690-702. doi: 10.1002/cpt.3238. Epub 2024 Mar 18. Clin Pharmacol Ther. 2024. PMID: 38494911
Pharmacokinetic/pharmacodynamic modelling in oncological drug development.
Karlsson MO, Anehall T, Friberg LE, Henningsson A, Kloft C, Sandström M, Xie R. Karlsson MO, et al. Among authors: kloft c. Basic Clin Pharmacol Toxicol. 2005 Mar;96(3):206-11. doi: 10.1111/j.1742-7843.2005.pto960310.x. Basic Clin Pharmacol Toxicol. 2005. PMID: 15733216 Free article. Review.
Role of TDM-based dose adjustments for taxane anticancer drugs.
Muth M, Ojara FW, Kloft C, Joerger M. Muth M, et al. Among authors: kloft c. Br J Clin Pharmacol. 2021 Feb;87(2):306-316. doi: 10.1111/bcp.14678. Epub 2020 Dec 18. Br J Clin Pharmacol. 2021. PMID: 33247980 Free article. Review.
195 results